Theranib Inc. https://validator.w3.org/feed/docs/rss2.html Funding Secured Home Theranib at BIOTECanada Coast to Coast Competition Theranib at BIO 2025 The Expanding Role of ALDH1A3 in Cancer Science Selective inhibition of ALDH1A3 impedes breast cancer growth and metastasis by blocking ALDH1A3-driven transcriptional programs About Us ALDH1A3 and Breast Cancer Progression Theranib’s US Patent Published Focus Areas Dr. Concettina La Motta US Patent Filing Contact Us Second-Round Financing (If Needed) Phase 1: Clinical Trials IND Submission Compound Development and Early Research GLP Toxicology Studies Combination Therapy News & Publications Pancreatic Cancer Glioblastoma Prostate Cancer Colorectal Cancer Breast Cancer Lung Cancer Tumor Progression Therapy Resistance Phase 2: In Vivo Efficacy Studies Initial Patent Filing Phase 1: Early Preclinical Work Careers Favorable Safety Profile Combination Synergy Metastasis Prevention High Potency and Specificity Targeted Action Dr. Paola Marcato Theranib at OBIO Investment Summit 2026